NCT06944704View on ClinicalTrials.gov

Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

March 19, 2025

Study Completion Date

March 19, 2025

Conditions
Hepatobiliary Disorders
Interventions
DRUG

Pentoxifylline

Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.

Trial Locations (1)

31111

Faculty of Pharmacy, Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06944704 - Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice | Biotech Hunter | Biotech Hunter